Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tomaralimab in Lower Risk MDS
NCT02363491Phase 2Completed
- Sponsor
- Opsona Therapeutics
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tomaralimab in myelodysplastic syndrome (MDS), sponsored by Opsona Therapeutics. Primary endpoints: Establishment of the dose and dose frequency at 8 weeks, Tolerability of OPN-305 as monotherapy at 32 weeks and 1 more. Started Jan 2015; status: completed.
02
Drugs
tomaralimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02363491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363491.